$7.67
4.13% day before yesterday
Nasdaq, Dec 27, 10:01 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$7.67
-1.06 12.14% 1M
+1.29 20.13% 6M
-3.58 31.82% YTD
-3.68 32.42% 1Y
-1.17 13.24% 3Y
+5.87 326.11% 5Y
-229.63 96.77% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.33 4.13%
ISIN
US02155H1014
Symbol
ALT
Sector
Industry

Key metrics

Market capitalization $545.53m
Enterprise Value $407.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8,157.60
P/S ratio (TTM) P/S ratio 10,910.60
P/B ratio (TTM) P/B ratio 4.09
Revenue growth (TTM) Revenue growth -81.36%
Revenue (TTM) Revenue $50.00k
EBIT (operating result TTM) EBIT $-99.51m
Free Cash Flow (TTM) Free Cash Flow $-78.12m
Cash position $139.42m
EPS (TTM) EPS $-1.55
P/E forward negative
P/S forward 381,756.47
EV/Sales forward 285,430.37
Short interest 33.04%
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Altimmune, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Altimmune, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.05 0.05
82% 82%
100%
- Direct Costs 2.10 2.10
-
4,200%
-2.04 -2.04
-
-4,080%
- Selling and Administrative Expenses 16 16
11% 11%
32,040%
- Research and Development Expense 79 79
17% 17%
158,700%
-97 -97
12% 12%
-194,840%
- Depreciation and Amortization 2.10 2.10
-
4,200%
EBIT (Operating Income) EBIT -100 -100
17% 17%
-199,020%
Net Profit -104 -104
32% 32%
-207,040%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Positive
The Motley Fool
9 days ago
Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day.
Neutral
GlobeNewsWire
10 days ago
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
Positive
Seeking Alpha
13 days ago
Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in P...
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website www.altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today